| Identification | Back Directory | [Name]
5-Methyl-N-phenyl-2-1H-pyridone-d5 ( Pirfenidone-d5 ) | [CAS]
1020719-62-3 | [Synonyms]
AMR69 D5
[2H5]-Pirfenidone
2(1H)-Pyridinone, 5-Methyl-1-phenyl-d5-
2(1H)-Pyridinone, 5-methyl-1-(phenyl-2,3,4,5,6-d5)-
Pirfenidone-d5 (5-Methyl-N-Phenyl-2-1H-Pyridone-d5)?
5-Methyl-N-phenyl-2-1H-pyridone-d5 ( Pirfenidone-d5 )
5-methyl-1-(2,3,4,5,6-pentadeuteriophenyl)pyridin-2-one
5-Methyl-1-(phenyl-2,3,4,5,6-d5)-2(1H)-pyridinone | [Molecular Formula]
C12H11NO | [MDL Number]
MFCD07369537 | [MOL File]
1020719-62-3.mol | [Molecular Weight]
185.222 |
| Chemical Properties | Back Directory | [Melting point ]
104-106°C | [storage temp. ]
-20°C Freezer | [solubility ]
Chloroform (Slightly), Ethanol, Ethyl Acetate, Methanol (Slightly) | [form ]
Solid | [color ]
White to Light Beige | [InChI]
InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3 | [InChIKey]
ISWRGOKTTBVCFA-UHFFFAOYSA-N | [SMILES]
O=C1C=CC(C)=CN1C1C([H])=C([H])C([H])=C([H])C=1[H] |
| Hazard Information | Back Directory | [Description]
Pirfenidone-d5 is intended for use as an internal standard for the quantification of pirfenidone by GC- or LC-MS. Pirfenidone is an orally bioavailable pyridone derivative with antifibrotic, anti-inflammatory, and antioxidant activities. It inhibits TGF-β1-stimulated increases in collagen type I, fibronectin, and Hsp47 expression in A549 lung cancer cells in a concentration-dependent manner. Pirfenidone (300 mg/kg per day) inhibits fibrosis and inhibits increases in collagen content, fibrocyte pool size, and the levels of chemokines CCL2 and CCL12 in lung in a mouse model of pulmonary fibrosis induced by bleomycin . In a mouse model of non-alcoholic steatohepatitis (NASH), pirfenidone inhibits fibrosis and increases in hepatocyte apoptosis, lobular inflammation, and hepatic expression of the fibrosis-related genes Col1a1, Timp1, Tgfb1, Pdgfb, and Fgf2 when administered at a dose of 280 mg/kg but has no effect on steatosis. Pirfenidone also inhibits NADPH-dependent lipid peroxidation in sheep liver microsomes and scavenges hydroxyl radicals (IC50s = ~6 and ~2.5 mM, respectively). Formulations containing pirfenidone have been used in the treatment of idiopathic pulmonary fibrosis. | [Chemical Properties]
Off-White Solid | [Uses]
A deuterated metabolite of Pirfenidone, a new drug to treat patients with kidney disease who have diabetes. | [References]
[1] CHIKARA KOMIYA. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis.[J]. Scientific Reports, 2017: 44754. DOI: 10.1038/srep44754
[2] MINORU INOMATA. Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis.[J]. Respiratory Research, 2014: 16. DOI: 10.1186/1465-9921-15-16
[3] H P MISRA C R. Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals.[J]. Molecular and Cellular Biochemistry, 2000, 204 1-2: 119-126. DOI: 10.1023/a:1007023532508
[4] KEIKO HISATOMI. Pirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells.[J]. BMC Pulmonary Medicine, 2012, 12: 24. DOI: 10.1186/1471-2466-12-24
[5] ANTJE MOELLER . The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?[J]. International Journal of Biochemistry & Cell Biology, 2008, 40 3: Pages 362-382. DOI: 10.1016/j.biocel.2007.08.011 |
|
| Company Name: |
BOC Sciences Gold
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|